Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) is now available.
NeuroScientific Biopharmaceuticals has started the first technology transfer manufacturing run for its StemSmart mesenchymal stem cell therapy at Q-Gen Cell Therapeutics in Brisbane. The move shifts StemSmart’s patented manufacturing process to a large-scale GMP contract manufacturer with the capacity to supply product for Phase 2 clinical trials and future commercial demand.
Q-Gen, one of Australia’s largest cell therapy manufacturers with 13 dedicated cleanrooms and a TGA licence, is working through a six-stage transfer program, including process mapping, engineering runs and regulatory audit. Completion of the transfer and validation is targeted for the second half of 2026, aligning with NSB’s planned Phase 2 trial initiation and laying the groundwork for entry into the roughly US$13 billion global Crohn’s disease market.
The partnership is intended to secure a robust, regulatory-compliant supply chain for StemSmart and supports the company’s broader commercialisation strategy. By scaling up manufacturing and integrating NSB’s technology into Q-Gen’s quality systems, the company aims to position StemSmart as a platform cell therapy across multiple inflammatory conditions, potentially strengthening its competitive standing in advanced cell therapeutics.
The most recent analyst rating on (AU:NSB) stock is a Sell with a A$0.09 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.
More about Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Ltd. is an Australian biotechnology company focused on developing novel therapies for immune-mediated inflammatory diseases. Its lead platform, StemSmart, is a patented mesenchymal stem cell therapy aimed initially at Crohn’s disease, with potential applications in transplant rejection, lung inflammatory diseases and graft-vs-host disease.
Average Trading Volume: 379,745
Technical Sentiment Signal: Sell
Current Market Cap: A$30.93M
For detailed information about NSB stock, go to TipRanks’ Stock Analysis page.